AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. EPRX
  4. [6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

[6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock EPRX logo
Eupraxia Pharmac

NASDAQ:EPRX

EPRX Rankings

#6138 Ranked by Market Cap
N/A Ranked by Dividends

EPRX Latest News

Jul 22, 2025
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
Jul 8, 2025
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
Jun 2, 2025
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
May 7, 2025
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025
May 6, 2025
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

EPRX Latest SEC Filings

Jul 8, 2025
[6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

EPRX Stock Data

192.96M
28.97M
22.56%
13.09%
0.44%
Biotechnology
Healthcare
Canada
Victoria